Summary The anti-tumour activity of CPT-l 1, a topoisomerase I inhibitor, was evaluated in four human neural-crest-derived paediatric tumour xenografts: one peripheral primitive neuroectodermal tumour (pPNET) (SK-N-MC) and three neuroblastomas. Two models, SK-N-MC and IGR-N835, were established in athymic mice from a previously established in vitro cell line. Two new neuroblastoma xenograft models, IGR-NB3 and IGR-NB8, were derived from previously untreated non-metastatic neuroblastomas. They exhibited the classic histological features of immature neuroblastoma along with N-myc amplification, paradiploidy, chromosome lp deletions and overexpression of the human mdrl gene. These tumour markers have been shown to be poor prognostic factors in children treated for neuroblastoma. CPT-11 was tested against advanced stage subcutaneous tumours. CPT-11 was administered i.v. using an intermittent (q4d x 3) and a daily x 5 schedule. The optimal dosage and schedule was 40 mg kg-' daily for 5 days. At this highest non-toxic dose, CPT-11 induced 100% tumour-free survivors on day 121 in mice bearing the pPNET SK-N-MC xenograft. For the three neuroblastoma xenografts, 38-100% complete tumour regressions were observed with a tumour growth delay from 38 to 42 days, and anti-tumour activity was clearly sustained at a lower dosage (27 mg kg-' day-'). The efficacy of five anti-cancer drugs commonly used in paediatric oncology or in clinical development was evaluated against SK-N-MC and IGR-N835. The sensitivity of these two xenografts to cyclophosphamide, thiotepa and cisplatin was of the same order of magnitude as that of CPT-11, but they were refractory to etoposide and taxol. In conclusion, CPT-11 demonstrated significant activity against pPNET and neuroblastoma xenografts. Further clinical development of CPT-11 in paediatric oncology is warranted.
Neuroblastomas are frequent malignant paediatric solid tumours, accounting for 6-8% of all malignancies in children. These tumours arise from the sympathetic tissue, outside the central nervous system, and belong to the group of primitive neuroectodermal tumours (PNETs) . At diagnosis, nearly 50% of neuroblastomas are metastatic, mainly to the bone marrow. Several biological tumour parameters such as N-myc gene amplification (Brodeur et al., 1984) , loss of heterozygosity of chromosome lp (Fong et al., 1989; Hayashi et al., 1989) , diploidy (Hayashi et al., 1989) and mdrl gene overexpression (Bourhis et al., 1989; Chan et al., 1991) have been identified as strong predictors of a poor outcome. Despite the use of intensive chemotherapy protocols, including high-dose chemotherapy followed by autologous bone marrow stem cell support, the survival of children treated for non-metastatic neuroblastoma with Nmyc amplification or for metastatic neuroblastoma (over 1 year of age) remains poor.
The group of peripheral PNETs (pPNETs) includes osseous and extraosseous Ewing's sarcomas along with neuroepitheliomas. Like neuroblastoma, pPNETs are neural-crest-derived tumours. The differential morphological diagnosis between extraosseous pPNETs and neuroblastoma sometimes proved difficult, until the t(l 1,22) reciprocal translocation was identified as specific to pPNET (Delattre et al., 1992) . These tumours are chemosensitive but the prognosis of patients with a metastatic or poorly chemosensitive pPNET remains poor.
New active drugs are therefore needed to improve further the survival ofpatients with neuroblastoma and pPNET. CPT-l 1, a semisynthetic water-soluble analogue of campthotecin, belongs to a new class of anti-cancer drugs, the DNA-topoisomerase I inhibitors. These compounds stabilise the cleavable complex (topoisomerase I -DNA) and induce consecutive lethal events that lead to cell death .
CPT-1 1 exhibited a wide spectrum of preclinical activity in vivo against murine and human solid tumours (Kunimoto et al., 1987; Kawato et al., 1991; Bissery et al., 1992; Houghton et al., 1993) . In addition, phase II studies in adults have shown promising results in several cancers such as colon and lung cancers (Masuda et al., 1993; Abigerges et al., 1995) .
CPT-1 1 may prove to be an interesting new drug for the treatment of cancer in children. In order to establish the rational basis for the clinical development of CPT-11 in paediatric oncology, we embarked on the preclinical evaluation of CPT-11 against specific paediatric tumour xenografts. The aims of the present study were; (1) to establish and characterise neuroblastoma and pPNET xenograft models; (2) to evaluate the anti-tumour activity of (3) to compare the activity of CPT-11 with that of other anti-cancer drugs.
Materials and methods

Animals
Female SPF-Swiss nude mice were bred in large-sized isolators in the Animal Experimentation Unit, at the Institut Gustave-Roussy (Villejuif, France). The (Biedler et al., 1973) . This cell line was originally classified as a neuroblastoma cell line. Further cytogenetic studies demonstrated the presence of the t(11,22) translocation, which is specific to Ewing's sarcoma and other pPNETs (Chen et al., 1995) . The SK-N-MC xenograft model was established by the subcutaneous injection of 107 cells per mouse in eight animals, which induced tumour growth in 100% of animals.
IGR-N835 was derived from a previously treated stage IV abdominal neuroblastoma with N-myc amplification (25 copies/haploid genome) in a 2-year-old girl (Bettan-Renaud et al., 1989) . The patient's tumour proved to be tumorigenic in six out of seven mice that had been injected subcutaneously with 107 cells obtained after mechanical dissociation of the tumour. In addition, a continuous in vitro cell line was obtained and characterised in terms of immunocytochemistry, cytogenetics and N-myc gene amplification and overexpression. An IGR-N835 xenograft tumour at passage 17 was kindly provided by J Benard and subsequently maintained in vivo by sequential passages.
IGR-NB3 and IGR-NB8 were derived from two previously untreated primary neuroblastomas. IGR-NB3 was derived from a stage III abdominal neuroblastoma with N-myc amplification (27 copies/haploid genome) in a 4-yearold boy. IGR-NB8 was derived from a stage III abdominal neuroblastoma with N-myc amplification (five copies/haploid genome) in a 5-year-old boy. The primary tumours of these two patients were refractory to conventional chemotherapy and these children eventually died of disease. Patient tumour fragments (3 x 3 mm) were obtained at diagnosis and transplanted subcutaneously in female athymic mice that had previously received total body irradiation at a dose of 5 Gy ('Co Eldorado). A successful take rate was observed in seven out of seven and two out of two mice for IGR-NB3 and IGR-NB8 respectively.
Xenografts were maintained in vivo in non-irradiated mice. Small fragments (3 x 3 mm) were obtained from a 1000-1500 mm3 tumour, and transplanted subcutaneously into the flanks of animals. The human origin of the four xenograft lines was confirmed by the analysis of lactate dehydrogenase (LDH) isoenzymes (data not shown).
Characterisation of xenograft models For histological analysis, fresh xenograft tissue specimens were fixed in acetic acid -formalin-ethanol (AFA, Carlo-Erba, Milano, Italy) and embedded in paraffin. The paraffinembedded sections were routinely stained with haematoxylin -eosin -saphranine (HES). Immunohistochemical analysis was then performed using the Dako L.SAB (labelledstreptavidin-biotin) kit (Dakopatts, Copenhagen, Denmark) after systematic pretreatment by microwave oven heating in an appropriate buffer. The following primary antibodies (Dakopatts) were used: monoclonal neuron-specific enolase (NSE) diluted 1: 40; chromogranine diluted 1: 50; MIC2 diluted 1: 50; common leucocyte antigen (CLA) diluted 1: 75 as a negative control. Histological analysis was performed for each xenograft model at first passage in mice and then every 3 -6 passages.
For the cytogenetic study of IGR-NB3 and IGR-NB8, fragments of fresh xenograft tumours were mechanically minced. The dissociated cells were then plated in RPMI-1640 medium with 20% fetal calf serum for a short culture. Cells were harvested after 6-16 h incubation with colcemid (0.001%). RHG banding was then performed after a hypotonic shock (potassium chloride 0.075 M for 30 min), as previously described (Dutrillaux et al., 1971) . Twenty mitoses were analysed for each tumour according to the ISCN nomenclature.
Southern blot analysis of N-myc and Northern blot analysis of the human mdrl gene transcript were performed as described previously (Ferrandis et al., 1994) . Genomic DNAs and RNAs were prepared from freshly frozen xenograft tumours according to a modified caesium chloride-guanidium isothiocyanate method. The human Nmyc probe was pNb-1 covering the second exon. Positive controls consisted of the SK-N-SH neuroblastoma and Y79 retinoblastoma cell lines, which contain one and 25 copies of N-myc respectively. The human mdrl gene probe was the complementary DNA probe HDR5A, which encompasses the coding regions of the gene. The mdrl gene transcript was measured and compared with that of the KB-8-5 cell line, which arbitrarily expresses 30 a.u. Qualitative and quantitative controls of the RNA preparations were provided by ethidium bromide staining whereas Southern blots were rehybridised with ,B-actin pseudogene.
The presence of the EWS -FLI fusion transcript in the SK-N-MC xenograft was detected by reverse transcriptasepolymerase chain reaction (RT-PCR) analysis of total RNA, as described previously (Delattre et al., 1992 Experimental design Drug activity was evaluated only against advanced-stage tumours. For each experiment, 3 x 3 mm tumour fragments were xenotransplanted subcutaneously (unilaterally or bilaterally) in 30-50 athymic mice aged 6-8 weeks. On day 0 of the treatment, mice bearing a 100 -300 mm3 subcutaneous tumour were pooled and randomly assigned to 2-4 groups of 5-10 mice (one control group, 1-3 treated groups at different dose levels). Animals bearing bilateral tumours were used only in two experiments (CPT-1 1 against IGR-NB3 and taxol against SK-N-MC). Animals with tumours outside the desired volume range were excluded. Two tumour perpendicular diameters were measured three times weekly with a caliper by the same investigator. Each tumour volume was calculated according to the following equation:
where d and D are the smallest and largest perpendicular tumour diameters respectively. Each group of mice was treated according to the average weight of the group. Animal body weights were recorded three times a week and mortality was checked daily. Body weight loss (BWL) was reported as the maximum treatment-related weight loss. The expreriments lasted until tumour volumes reached 1500-2000 mm3. The experiment was stopped after 120 days when there were tumour free survivors.
Treatment
CPT-1 1 was administered i.v. in a caudal vein at a daily dose ranging from 27 to 100 mg kg-'. Two schedules were studied: an intermittent schedule (one dose every 4 days for a total of three doses, q4d x 3) and a daily x 5 schedule. Cyclophosphamide and thiotepa were administered once i.p. at a dose of 400 and 24 mg kg-' respectively. These dosages represented 90% of the 10% lethal dose (LDIo) of these two drugs, as previously determined in non-tumour-bearing female athymic Swiss mice. Etoposide was administered i.v. daily x 5 at a dose of 17 and 25 mg kg-' day-'. Cisplatin was administered i.v. on day 0 and day 4 at a dose of 3.5-10 mg kg-1 day-1. Taxol was administered i.p. over 7 days at a daily dose ranging from 12 to 20 mg kg -1 over 7 days. Therapeutic experiments were carried out from passages 3 to 17 for SK-N-MC, from passages 10 to 33 for IGR-N835 and at passage 5 for IGR-NB3 and IGR-NB8. This study intended to evaluate the anti-tumour activity of CPT-11, cisplatin, etoposide and taxol at the highest non-toxic dose, defined as the dose level that induced no toxicity-related deaths and a maximum BWL of less than 15%, as observed in each multiple dose-level experiment. The anti-tumour activity of cyclophosphamide and thiotepa was evaluated at 90% of the historical LDI0 dosage. 
Evaluation of anti-tumour activity
The activity of each drug tested was evaluated according to three criteria: (1) the number of complete and partial tumour regressions; (2) the tumour growth delay (TGD); (3) the number of tumour-free survivors (TFSs). Complete regression (CR) was defined as a tumour regression beyond the palpable limit (15 mm3) and partial regression (PR) as a tumour regression greater than 50% of the initial tumour volume. CR and PR had to be observed for at least two consecutive tumour measurements in order to be retained. TGD was defined as the difference between the treated group and the control group in the median time to reach a tumour volume that was five times greater than the initial tumour volume (Friedman et al., 1988) . Tumour-free survivors were defined as animals free of palpable tumour at the end of the experiment (at least 120 days).
Results
Characterisation of the xenograft models SK-N-MC xenografts showed the microscopic features of an immature PNET, namely uniform dense sheets of small rounded cells with regular nuclei, frequent mitoses and scant cytoplasm (Figure la) . Neither rosette formation nor fibrous septa were observed. Immunohistochemical analysis showed negativity for NSE, chromogranine and MIC2. No N-myc amplification was observed. The diagnosis of pPNET was ascertained by the presence of the EWS -FLI fusion transcript as identified by RT-PCR (Figure 2 ). IGR-N835, IGR-NB3 and IGR-NB8 showed the classic microscopic appearance of immature neuroblastomas, namely small uniform rounded cells more or less arranged in nests that are separated by a fibrillar stroma (Figure lb) . No ganglion cells were observed. All three xenografts exhibited positivity for NSE and chromogranine, along with N-myc amplification (Table I) . The previously reported cytogenetic study of IGR-N835 showed a paradiploid mode with a t(1;10) and t(11;17) (Bettan-Renaud et al., 1989) ( Table I ). The IGR-NB3 xenograft was diploid with numerous double minute chromosomes (DMS) and two recurrent markers, namely deletion of the short arms of chromosomes 1 and 2 [del(lp) and del(2p)] (Table I, Figure 3a) . No cytogenetic study could be performed on the patient's tumour. IGR-NB8 was paradiploid with a del(lp), a pericentric inversion of chromosome 2 and the addition of material on the long arm of chromosome 6. One of the breakpoints (2p24) of the pericentric inversion is implicated in the N-myc gene. The same chromosome markers were found in the patient's tumour, surgically removed after chemotherapy (Figure 3b) , strongly suggesting that the chromosome alterations found in the xenograft were not acquired during xenografting. It was not possible to check whether the pericentric inversion of chromosome 2 was constitutional or not because of a chemotherapy-induced low lymphocyte blood count. Finally, the IGR-NB3 and IGR-NB8 neuroblastoma xenografts exhibited overexpression of the human mdrl gene whereas the SK-N-MC and IGR-N835 xenografts did not (Table I) .
The tumour take rate of the four xenografts ranged from 81% to 99% (Table I) . They showed reproducible growth kinetics as evaluated by measuring the doubling time and based on the unchanged histological features throughout the experiments.
Toxicity of CPT-JJ in tumour-bearing mice The optimal dosage and schedule during short-term administration (intermittent or daily x 5 schedules) were first studied in animals bearing the SK-N-MC and IGR-N835 xenografts.
During the first experiments, toxicity-related deaths were observed immediately after the i.v. injection of doses greater than 45 mg kg-'. These immediate toxicity-related deaths were dose dependent, with five deaths after eight injections and two deaths after 23 injections at 100 mg kg-' and 66 mg kg-' dose levels respectively. This toxicity was related neither to the speed of injection nor to the vehicle in which CPT-11 was formulated (D-sorbitol 225 mg, lactic acid 4.5 mg, sodium hydroxide qsp pH 3.5, in distilled water qsp 5 ml). Owing to the dose dependent immediate toxicity, the highest non-toxic dose using an intermittent schedule was 45 mg kg-day-' q4d x 3 (total dose, 135 mg kg-'). Using the daily schedule, acute toxicityrelated deaths were observed at the 60 mg kg-1 day-' x 5 dose level with five out of eight mice dying on days 7 -10.
The optimal dosage was 40 mg kg-1 day-1 x 5 (total dose, 200 mg kg-') with no toxicity-related deaths and a maximum body weight loss ranging from 0.5% to 11%. No diarrhoea was observed during any of the experiments. Animals treated with the dailyx 5 schedule were observed up to a maximum of 120 days. Out of the 92 mice treated at dosages ranging from 27 to 60 mg kg-' day-' that survived beyond day 10 (the upper limit for acute toxicityrelated death), one delayed death was observed on day 48 (after a dose of 66 mg kg-', q4d x 3). No particular macroscopic features were found at autopsy. Anti-tumour activity of CPT-JJ SK-N-MC was found to be the most sensitive xenograft of the four models tested, with 100% complete regressions and the longest tumour growth delays at the maximum tolerated dosage, regardless of the schedule (Table II) . With the intermittent schedule, the maximum tolerated dose was 45 mg kg-' injection (total dose, 135 mg kg-'). This dosage produced seven out of eight SK-N-MC tumour-free survivors on day 122. The daily x 5 schedule allowed a higher dose to be administered, i.e. 40 mg kg-' injection (total dose, 200 mg kg-'). This dosage produced eight out of eight SK-N-MC tumour-free survivors (Figures 4a and b) . In addition, CPT-1 1 activity was clearly sustained when administered at a lower dosage (27 mg kg-' day-' x 5) with 100% tumour-free survivors on day 121. CPT-11 was also very active against both IGR-NB3 and IGR-NB8, two neuroblastoma models overexpressing the mdrl gene. Using the daily schedule at the highest dose tested, complete regressions (38% and 100%) with tumour growth delays of 42 and 46 days were achieved in IGR-NB3 and IGR-NB8 respectively (Figure 4e-h) . The anti-tumour activity against IGR-NB8 was clearly retained at a lower dosage.
The least sensitive model was the mdr-negative IGR-N835 neuroblastoma xenograft. The best schedule was the daily x 5 schedule, as seen with the SK-N-MC model. At the highest dosage tested, one partial and seven out of eight complete regressions were obtained with a 38 day tumour growth delay ( Figure 4c and d) . Again, activity persisted at lower doses. When the same total dose level (135 mg kg-') was considered, the intermittent schedule (q4d x 3) induced only one CR out of eight tumours with a TGD of 12 days whereas the daily schedule (one daily dose for 5 days) induced six out of eight CRs with a TGD of 26 days (Table II) .
Activity of other anti-cancer drugs
The SK-N-MC xenograft model, which was highly sensitive to CPT-11, was also highly sensitive to cyclophosphamide and thiotepa, which induced nine out of ten and six out of eight long-term tumour-free survivors respectively (Table III) . Cisplatin, given at its highest non-toxic dose (7 mg kg-' day-' x 2) induced one CR out of eight tumours and one tumour-free survivor. Etoposide and taxol failed to induce any complete tumour regression or any significant tumour growth delay. IGR-N835 was sensitive to alkylating agents with significant TGDs of 13, 21 and 28 days being observed with thiotepa, cisplatin and cyclophosphamide CPT-11 against neuroblastoma xenografts G Vassal et al $ 541 respectively (Table III) . In addition, complete regressions were obtained with cyclophosphamide and cisplatin. Thus, alkylating agents at the tested doses were less active than CPT-11 against the neuroblastoma IGR-N835 xenograft. Etoposide and taxol failed to demonstrate any anti-tumour activity against IGR-N835.
Discussion
Human tumour xenografts are now well-established tools for preclinical screening of anti-cancer drugs and an integral part of the current NCI and EORTC disease-oriented strategies for drug screening . Xenografts are believed to predict the histological type of human cancers likely to be sensitive or resistant to a new anti-cancer agent. This property led to the design of so-called 'preclinical phase II studies ' (Boven et al., 1988) of anti-cancer drugs, which would serve to orient future clinical development targeting histology. Such disease-oriented preclinical development of new drugs was considered particularly applicable to paediatric oncology for two major reasons. Cancer is rare in children and survival rates are high. Consequently, the number of children suffering from cancer who are eligible for phase I and II studies is considerably lower than that of adults eligible for such studies. Preclinical phase II studies against specific paediatric tumour xenografts may help to select new drugs whose clinical development should be rapidly promoted in paediatric oncology.
Our first objective was to establish subcutaneous xenograft models for the preclinical evaluation of new anti-cancer drugs against neuroblastoma and pPNET. The panel comprises one PNET (SK-N-MC) and three neuroblastoma models. SK-N-MC was at the outset classified as a neuroblastoma cell line (Biedler et al., 1973) . Later on, this cell line was reclassified in the peripheral PNET histology group because of the absence of N-myc amplification and the presence of a t(11;21) reciprocal translocation (Chen et al., 1995) . This was confirmed in our study by the presence of the EWS-FLI fusion transcript in xenografts derived from the SK-N-MC cell line. Although often used as a neuroepithelioma cell line, the histological features of SK-N-MC xenografts correspond to those of an immature peripheral PNET, without the classic morphological and immunohistochemical (staining with MIC2 antibodies) features of a neuroepithelioma.
The panel of neuroblastoma xenograft models used in this study comprises a previously reported in vitro cell line (IGR-N835) established in vivo (Bettan-Renaud et al., 1989) , and two newly derived neuroblastoma xenograft lines (IGR-NB3 and IGR-NB8). IGR-N835 was established from a previously derived from primary refractory non-metastatic neuroblastotreated metastatic neuroblastoma with N-myc amplification. mas with N-myc amplification; (2) they exhibited diploidy or The two new xenograft models also exhibited the features paradiploidy, chromosome lp deletion, N-myc amplification consistent with poor prognosis neuroblastomas: (1) they were and overexpression of mdrl. This is in good agreement with (Potmesil, 1994) . A recent up-front phase II study of topotecan showed a 37% response rate in children with a stage IV neuroblastoma (Kretschmar et al., 1995) . Recently, Tanizawa showed that SN38, the active metabolite of CPT-11, was the most potent compound in terms of in vitro cytotoxicity and the extent of DNA damage, compared with topotecan, camptothecin and 9-aminocamptothecin .
The work presented here demonstrates that CPT-1 is highly active against three neuroblastoma xenografts as it induced complete regressions and significant tumour growth delays in all models treated with short-term schedules (less than 2 weeks). In addition, the pPNET xenograft model proved to be highly sensitive with 100% of tumour-free survivors. The intermittent schedule was consistently found to be less effective than the daily schedule. CPT-1 1 is clearly active against neuroblastoma and pPNET xenografts, as its anti-tumour activity was retained at doses lower than the optimal dosage. These results are in good agreement with those of Komuro et al. (1994) who showed that CPT-11, administered i.p., induced significant tumour growth inhibition in the TNB9 neuroblastoma xenograft model, although no complete tumour regression was reported. CPT-11 was also found to be active against other paediatric cancer (Vassal et al., 1994) . Houghton showed that CPT-11 active against five of six childhood rhabdomyosarcoma xenograft models, even at dosages below the maximum tolerated dose (MTD) (Houghton et al., 1993) . In addition, a recent study suggested that the use of protracted schedules may increase the therapeutic activity of CPT-11 (Houghton et al., 1995) .
Previous studies have shown that CPT-11 is active against multidrug-resistant cell lines (Kunimoto et al., 1987; Tsuruo et al., 1988) . Houghton also found that CPT-11 retained its activity in vivo against a vincristine-resistant rhabdomyosarcoma xenograft (Houghton et al., 1993) . This is important as the human mdrl gene is overexpressed in neuroblastomas and several clinical studies have noted a relationship between mdrl overexpression and a poor prognosis in neuroblastoma patients (Bourhis et al., 1989; Chan et al., 1991) . It is noteworthy that our study demonstrates CPT-11 activity against neuroblastoma xenografts overexpressing the human mdrl gene.
The activity of five anti-cancer drugs was evaluated against SK-N-MC and IGR-N835 to validate our models in comparison with the established chemosensitivity of pPNETs and neuroblastomas in children. Cyclophosphamide and etoposide are currently used in conventional chemotherapy protocols to treat patients with neuroblastoma and Ewing's sarcoma (Hayes et al., 1989; Meresse et al., 1993; Kushner et al., 1994) . Cisplatin is a major drug used to treat neuroblastoma (Philip et al., 1987; Kushner et al., 1994) . Thiotepa is an alkylating agent used at a high dose before autologous bone marrow stem cell support in adult and childhood malignancies (Wolff et al., 1990) . Taxol, a new anti-cancer agent, is currently being investigated in phase I and II clinical trials in children with solid tumours and leukaemia (Hurwitz et al., 1993; Kretschmar et al., 1995) . The two xenografts were clearly sensitive to alkylating agents (cyclophosphamide, thiotepa) and cisplatin, with SK-N-MC being more sensitive than IGR-N835. This is in good agreement with the established sensitivity of pPNETs and neuroblastomas (Hayes et al., 1989; Meresse et al., 1993; Kushner et al., 1994) . Conversely, the two xenografts were refractory to taxol and etoposide. A recent up-front phase II study on taxol has shown an 18% response rate in neuroblastoma patients (Kretschmar et al., 1995) . Etoposide is widely used in paediatric oncology in combination with other drugs such as cyclophosphamide and platinum compounds (cisplatin or carboplatin) (Philip et al., 1987; Meresse et al., 1993) . However, phase II studies of singleagent etoposide showed very low response rates (<10%) in neuroblastoma and Ewing's sarcoma patients (Kung et al., 1988) . Thus, the CPT-11 activity was observed in two xenografts, which seems to reflect the sensitivity of neuroblastomas and pPNETs observed in children.
In conclusion, CPT-l 1 was found to be highly active against pPNET and neuroblastoma xenografts that exhibited the biological features of poor prognosis tumours in children. The high activity of CPT-11 observed in this study compared with that of conventional anti-cancer drugs used to treat children with neuroblastoma and pPNET suggests that CPT-11 deserves prompt evaluation in paediatric oncology.
